Aroa Biosurgery Limited (ASX:ARX)

Market Cap	134.51M
Revenue (ttm)	70.08M
Net Income (ttm)	-6.99M
Shares Out	344.90M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	57.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,632
Average Volume	824,424
Open	0.4050
Previous Close	0.4000
Day's Range	0.3900 - 0.4100
52-Week Range	0.3500 - 0.8150
Beta	0.49
RSI	41.21
Earnings Date	Apr 29, 2025

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ARX

Financial Performance

In 2023, Aroa Biosurgery's revenue was 69.07 million, an increase of 9.01% compared to the previous year's 63.36 million. Losses were -10.63 million, 2583.8% more than in 2022.

Financial numbers in NZD